Therapeutic nuclear medicine: Theranostic radiopharmaceuticals for metastatic cancer -focusing on targeted alpha therapy (Co-lead, South-Eastern Norway Regional Health Authority Grant), SIMPLERAD (Co-lead WP4, funded by the European Union), Biodistribution and dosimetry in a phase 1 trial of 224-Ra-CaCO3 particles (funded by sponsor), Dose-effects for a novel 177-Lu based treatment of non-Hodgkin lymphoma (South-Eastern Norway Regional Health Authority Research Grant), Simulation tools and quantitative 90-Y PET/CT for Selective Internal Radiation Therapy (South-Eastern Norway Regional Health Authority Innovation Grant), Dosimetry-based treatment planning of 131-I therapy.
Other studies: Quantitative PET parameters as predictors for patient outcome (part of different lymphoma trials), radiomics investigations, novel PET tracers for multiple myeloma assessments, and various technical projects related to image reconstruction and analyses.
Kvassheim M, Tornes AJK, Juzeniene A, Stokke C, Revheim MR(2023) Imaging of 212Pb in mice with a clinical SPECT/CT EJNMMI Phys, 10(1), 47 DOI 10.1186/s40658-023-00571-6, PubMed 37603123
Nørgaard JN, Abildgaard N, Lysén A, Tsykunova G, Vangsted AJ, João C, Remen N, Nielsen LK, Osnes L, Stokke C, Connelly JP, Revheim MR, Nordic Myeloma Study Group (NMSG), Schjesvold F(2023) Intensifying treatment in PET-positive multiple myeloma patients after upfront autologous stem cell transplantation Leukemia(in press) DOI 10.1038/s41375-023-01998-7, PubMed 37568010
Meier IM, Eikemo M, Trøstheim M, Buen K, Jensen E, Gurandsrud Karlsen S, Reme SE, Berna C, Leknes S, Ernst G(2023) Factors associated with use of opioid rescue medication after surgery Reg Anesth Pain Med(in press) DOI 10.1136/rapm-2023-104412, PubMed 37479238
Get in touch
Contact information Group Leader Caroline Stokke, PhD, Assoc. Prof., Department of Physics and Computational Radiology, carsto@ous-hf.no, (0047) 98685214